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Abstract 
Malignant melanoma is the most aggressive form of skin cancer and incidence rates 
are on the rise. Despite recent improvements in treatment options, the disease still re-
mains lethal. Which calls for expedited solutions. In this thesis I will discuss three studies, 
which have not only contributed new knowledge to the research community but also led 
to development of tools used in cancer research.  
In the first paper we developed a platform of patient-derived xenografts (PDXes) 
from metastatic melanoma patients. We show that PDXes can accurately predict clinical 
treatment responses and that the xenografts can be established in time to benefit the 
patients. Thus, the platform can be used for multiple pre-clinical and clinical purposes. 
In the second paper we compared the transcriptome of cell line-derived xenografts 
(CDXes) and PDXes. The initial aim was to investigate if CDXes would be transcription-
ally similar to PDXes and could therefore be used as in vitro surrogates for the PDXes. 
Instead, we identified a significant transcriptional difference between CDXes and PDXes, 
mainly explained by the pseudo hypoxia experienced by the cell lines once they are trans-
planted to the physiological environment.  
In the third study, we ran a pre-clinical trial in malignant melanoma PDX mouse 
models with the aim of identifying a predictive biomarker of the MTH1 inhibitor, Ka-
ronudib. By comparing the genomic and transcriptomic profiles of the responding and 
non-responding PDXes we identified that Karonudib has cytotoxic effect independent of 
those profiles. Also, we discovered that Karonudib causes cytotoxic effect beyond MTH1 
inhibition.  
Taken together, our data shows that PDX models predict clinical responses and can 
be used to test drugs pre-clinically, and argues that pre-clinical testing in PDX models is 
superior to cell line based drug testing.  
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